Comparative Pharmacology
Head-to-head clinical analysis: LUSEDRA versus PATHILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUSEDRA versus PATHILON.
LUSEDRA vs PATHILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors, decreasing gastrointestinal motility and gastric acid secretion.
5 mg orally once daily.
1-2 mg orally every 4-6 hours; maximum 12 mg/day. Alternatively, IM: 1-2 mg every 4-6 hours.
None Documented
None Documented
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Terminal elimination half-life approximately 2-4 hours; may be prolonged in elderly or patients with hepatic/renal impairment.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal (20-30%); minor metabolism via hepatic ester hydrolysis.
Category C
Category C
Anticholinergic
Anticholinergic